These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20978926)

  • 1. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).
    Balagula Y; Barth Huston K; Busam KJ; Lacouture ME; Chapman PB; Myskowski PL
    Invest New Drugs; 2011 Oct; 29(5):1114-21. PubMed ID: 20978926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.
    Deming DA; Cavalcante LL; Lubner SJ; Mulkerin DL; LoConte NK; Eickhoff JC; Kolesar JM; Fioravanti S; Greten TF; Compton K; Doyle AG; Wilding G; Duffy A; Liu G
    Invest New Drugs; 2016 Apr; 34(2):168-75. PubMed ID: 26666244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
    Dombi E; Baldwin A; Marcus LJ; Fisher MJ; Weiss B; Kim A; Whitcomb P; Martin S; Aschbacher-Smith LE; Rizvi TA; Wu J; Ershler R; Wolters P; Therrien J; Glod J; Belasco JB; Schorry E; Brofferio A; Starosta AJ; Gillespie A; Doyle AL; Ratner N; Widemann BC
    N Engl J Med; 2016 Dec; 375(26):2550-2560. PubMed ID: 28029918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
    Tai WM; Yong WP; Lim C; Low LS; Tham CK; Koh TS; Ng QS; Wang WW; Wang LZ; Hartano S; Thng CH; Huynh H; Lim KT; Toh HC; Goh BC; Choo SP
    Ann Oncol; 2016 Dec; 27(12):2210-2215. PubMed ID: 27681866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.
    Patel SP; Kim KB
    Expert Opin Investig Drugs; 2012 Apr; 21(4):531-9. PubMed ID: 22394161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials.
    Patel P; Howgate E; Martin P; Carlile DJ; Aarons L; Zhou D
    Br J Clin Pharmacol; 2018 Jan; 84(1):52-63. PubMed ID: 28833380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma.
    Sacco JJ; Jackson R; Corrie P; Danson S; Evans TRJ; Ochsenreither S; Kumar S; Goodman A; Larkin J; Karydis I; Steven N; Lorigan P; Plummer R; Patel P; Psarelli E; Olsson-Brown A; Shaw H; Leyvraz S; Handley L; Rawcliffe C; Nathan P
    Eur J Cancer; 2024 May; 202():114009. PubMed ID: 38547774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.
    Hubbard JM; Yin J; Schenk EL; Qin R; Reid JM; Strand C; Fiskum J; Menefee M; Lin G; Doyle LA; Ivy P; Erlichman C; Adjei A; Haluska P; Costello BA
    Invest New Drugs; 2022 Feb; 40(1):115-123. PubMed ID: 34515877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma.
    Prado CM; Bekaii-Saab T; Doyle LA; Shrestha S; Ghosh S; Baracos VE; Sawyer MB
    Br J Cancer; 2012 May; 106(10):1583-6. PubMed ID: 22510747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.
    Hochster HS; Uboha N; Messersmith W; Gold PJ; ONeil BH; Cohen D; Denlinger C; Cohen S; Leichman CG; Leichman L; Lenz HJ
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):17-23. PubMed ID: 25322874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines.
    Ma BB; Lui VW; Cheung CS; Lau CP; Ho K; Hui EP; Tsui SK; Ng MH; Cheng SH; Ng PK; Tsao SW; Chan AT
    Invest New Drugs; 2013 Feb; 31(1):30-8. PubMed ID: 22565394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders.
    Schad K; Baumann Conzett K; Zipser MC; Enderlin V; Kamarashev J; French LE; Dummer R
    Clin Cancer Res; 2010 Feb; 16(3):1058-64. PubMed ID: 20103661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
    LoRusso PM; Infante JR; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; Cohen RB
    BMC Cancer; 2017 Mar; 17(1):173. PubMed ID: 28264648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
    Infante JR; Cohen RB; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; LoRusso PM
    Invest New Drugs; 2017 Oct; 35(5):576-588. PubMed ID: 28424891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.
    Coleman RL; Sill MW; Thaker PH; Bender DP; Street D; McGuire WP; Johnston CM; Rotmensch J
    Gynecol Oncol; 2015 Jul; 138(1):30-5. PubMed ID: 25887099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermatologic Effects of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1: Clinical Challenges and Therapeutic Management.
    Borgia P; Piccolo G; Santangelo A; Chelleri C; Viglizzo G; Occella C; Minetti C; Striano P; Diana MC
    J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38542016
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.
    Lacouture ME; Anadkat MJ; Bensadoun RJ; Bryce J; Chan A; Epstein JB; Eaby-Sandy B; Murphy BA;
    Support Care Cancer; 2011 Aug; 19(8):1079-95. PubMed ID: 21630130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
    Carvajal RD; Schwartz GK; Mann H; Smith I; Nathan PD
    BMC Cancer; 2015 Jun; 15():467. PubMed ID: 26059332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Multifocal serous chorioretinopathy secondary to the use of MEK inhibitors: Illustration and example of management through two case reports].
    Coutu A; Farguette F; Jeannin G; Chiambaretta F
    J Fr Ophtalmol; 2016 Jan; 39(1):55-63. PubMed ID: 26747016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens.
    Bennouna J; Lang I; Valladares-Ayerbes M; Boer K; Adenis A; Escudero P; Kim TY; Pover GM; Morris CD; Douillard JY
    Invest New Drugs; 2011 Oct; 29(5):1021-8. PubMed ID: 20127139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.